Michael W. Schuster

Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster et al. · New England Journal of Medicine · 2005 · 2.5K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline

Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster et al. · British Journal of Haematology · 2009 · 308 citations

Medicine, Pharmacology, Pharmacotherapy +14

Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study

Asher Chanan‐Khan, Pieter Sonneveld, Michael W. Schuster et al. · Journal of Clinical Oncology · 2008 · 266 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +10

Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials

Sundar Jagannath, Paul G. Richardson, Pieter Sonneveld et al. · Leukemia · 2006 · 265 citations

Life Sciences, Hematology, Oncology +16

Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma

John P. Leonard, Morton Coleman, Jamie Ketas et al. · Clinical Cancer Research · 2004 · 227 citations

Pharmacy, Hematology, Pharmacology +17